Articles From: Steelcase Inc. Annual Meeting of Shareholders Announced to Stemline Therapeutics Provides Second Quarter 2014 Financial Results and Corporate Update


GRAND RAPIDS, Mich., July 2, 2014 (GLOBE NEWSWIRE) -- Steelcase Inc. (NYSE:SCS) will hold its Annual Meeting of Shareholders on Wednesday, July 16, 2014, via live webcast only beginning at 11:00 am EDT.
Sign-up for Steelcase Inc. Annual Meeting of Shareholders Announced investment picks
GRAND RAPIDS, Mich., Sept.
Sign-up for Steelcase Inc. to Webcast Second Quarter Conference Call investment picks
2014/6/16
CHICAGO , June 16, 2014 /PRNewswire/ -- Steelcase today announced that its family of brands and designers has won several top honors at NeoCon 2014, North America's largest design exhibition and conference for commercial interiors.
Sign-up for Steelcase Receives Top Honors at NeoCon 2014 investment picks
GRAND RAPIDS, Mich., June 26, 2014 (GLOBE NEWSWIRE) -- Steelcase Inc. (NYSE:SCS) today reported first quarter revenue of $723.1 million and net income of $21.0 million, or diluted earnings per share of $0.17. Excluding net restructuring benefits, adjusted earnings were $0.12 per share.
Sign-up for Steelcase Reports First Quarter Results investment picks
JACKSONVILLE, Fla., Sept.
Sign-up for Stein Mart Announces Six New Store Openings This Fall investment picks
JACKSONVILLE, Fla., Sept.
Sign-up for Stein Mart, Inc. Reports August Sales investment picks
JACKSONVILLE, Fla., Aug.
Sign-up for Stein Mart, Inc. Reports July Sales investment picks
JACKSONVILLE, Fla., July 10, 2014 (GLOBE NEWSWIRE) -- Stein Mart, Inc. (Nasdaq:SMRT) today reported total sales for the five-week period ended July 5, 2014 of $113.2 million, a 3.8 percent increase over total sales of $109.0 million for the five-week period ended July 6, 2013.
Sign-up for Stein Mart, Inc. Reports June Sales investment picks
2014/8/21
Second Quarter Highlights Total sales increased 2.5 percent and comparable store sales, 1.3 percent.
Sign-up for Stein Mart, Inc. Reports Second Quarter 2014 Results investment picks
JACKSONVILLE, Fla., July 31, 2014 (GLOBE NEWSWIRE) -- Stein Mart, Inc. (Nasdaq:SMRT) announced today that Jay Stein, Chief Executive Officer, and Gregory W.
Sign-up for Stein Mart, Inc. to Present at Canaccord Genuity 34th Annual Growth Conference investment picks
NASSAU, The Bahamas, July 29, 2014 (GLOBE NEWSWIRE) -- Steiner Leisure Limited (Nasdaq:STNR) today announced that it has entered into an amendment to its agreement with Windstar Cruises, extending the term of its original agreement through April 2017, with automatic successive one-year renewal terms thereafter, cancelable by either party with 90 days advance written notice.
Sign-up for Steiner Leisure Limited Announces Renewal of Agreement With Windstar Cruises investment picks
NASSAU, The Bahamas, July 30, 2014 (GLOBE NEWSWIRE) -- Steiner Leisure Limited (Nasdaq:STNR) today announced financial results for the second quarter ended June 30, 2014.
Sign-up for Steiner Leisure Limited Announces Second Quarter 2014 Financial Results investment picks
NASSAU, The Bahamas, July 3, 2014 (GLOBE NEWSWIRE) -- Steiner Leisure Limited (Nasdaq:STNR) , announced today that it will release its Second Quarter 2014 earnings on Wednesday, July 30, 2014 after market close.
Sign-up for Steiner Leisure Limited Announces Second Quarter 2014 Financial Results on July 30, 2014 investment picks
Stellus Capital Investment Corporation (the “Company”) (NYSE: SCM) announced today that on July 7, 2014, its Board of Directors declared a regular monthly dividend for each of July, August and September for an aggregate of $0.34 per share.
Sign-up for Stellus Capital Investment Corporation Declares Third Quarter 2014 Regular Dividend of $0.34 Per Share investment picks
Stellus Capital Investment Corporation (the “Company”) (NYSE: SCM) announced today that it has postponed its 2014 annual meeting of stockholders originally scheduled for June 26, 2014.
Sign-up for Stellus Capital Investment Corporation Postpones 2014 Annual Meeting of Stockholders to July 7, 2014 investment picks
Stellus Capital Investment Corporation (the “Company”) (NYSE: SCM), a business development company, today announced that its wholly-owned subsidiary, Stellus Capital SBIC, LP ("Stellus SBIC"), has received approval for a license from the United States Small Business Administration ("SBA") to operate as a Small Business Investment Company ("SBIC"). The license will allow Stellus SBIC to obtain leverage by issuing SBA-guaranteed debentures, subject to the issuance of a capital commitment by the SBA and customary procedures.
Sign-up for Stellus Capital Investment Corporation Receives Approval for Its Subsidiary’s SBIC License investment picks
Stellus Capital Investment Corporation (NYSE:SCM) (“Stellus” or “the Company”) today announced financial results for its second fiscal quarter ended June 30, 2014.
Sign-up for Stellus Capital Investment Corporation Reports Results for Its Second Fiscal Quarter Ended June 30, 2014 investment picks
Stellus Capital Investment Corporation (NYSE: SCM) will release its financial results for the second quarter ended June 30, 2014 on Monday, August 11, 2014 before the market opens.
Sign-up for Stellus Capital Investment Corporation to Report Second Quarter 2014 Financial Results and Hold Conference Call investment picks
NEWARK, Calif., July 18, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) , today announced that it has closed its previously announced offering of common stock and short term warrants.
Sign-up for StemCells, Inc. Announces Closing of $20 Million Offering investment picks
NEWARK, Calif., June 20, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) yesterday announced that based on positive interim results, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration (AMD) in order to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study, later this year.
Sign-up for StemCells, Inc. Announces Closure of Enrollment in Phase I/II Dry Age-Related Macular Degeneration Trial investment picks
NEWARK, Calif., July 15, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) , today announced its intent to offer and sell 11,299,435 shares of common stock and short term warrants for the purchase of up to 9,604,520 additional shares of common stock to two well recognized institutional biotechnology investors, subject to market and other conditions, for gross proceeds of $20 million, before deducting placement fees and other offering expenses.
Sign-up for StemCells, Inc. Announces Proposed $20 Million Offering investment picks
NEWARK, Calif., Aug.
Sign-up for StemCells, Inc. Announces Webcast to Discuss Second Quarter 2014 Financial Results investment picks
NEWARK, Calif., July 7, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today the appointment of Alan Trounson, Ph.D. to its Board of Directors.
Sign-up for StemCells, Inc. Appoints Dr. Alan Trounson to Board of Directors investment picks
NEWARK, Calif., June 19, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) reported positive interim results from its Phase I/II clinical trial of the Company's proprietary HuCNS-SC ® human neural stem cell platform in dry age-related macular degeneration (AMD) yesterday evening at the 12 th annual meeting of the International Society for Stem Cell Research (ISSCR) in Vancouver, Canada.
Sign-up for StemCells, Inc. Interim Results Show Improvement in Visual Function and Slowing of Disease Progression in Phase I/II Dry AMD Trial investment picks
NEWARK, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will be a panelist at the 2014 BIO International Convention on June 25, 2014 at 4:15 pm PDT.
Sign-up for StemCells, Inc. President and CEO Martin McGlynn to Present on a Regenerative Medicine Panel at the 2014 BIO International Convention investment picks
NEWARK, Calif., June 17, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today one promotion and three new appointments to the Company's executive team.
Sign-up for StemCells, Inc. Strengthens Senior Executive Team investment picks
NEW YORK, July 28, 2014 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the opening of its SL-401 Investigational New Drug (IND) and initiation of a broad clinical development program including trials in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML). SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on cancer stem cells (CSCs) and tumor bulk of many hematologic cancers.
Sign-up for Stemline Therapeutics Announces Opening of SL-401 Corporate IND and Start of Clinical Trials in BPDCN and AML investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Steelcase Inc. Annual Meeting of Shareholders Announced to Stemline Therapeutics Provides Second Quarter 2014 Financial Results and Corporate Update
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices